Evidence or Theory? Antiaggregation Scheme after Peripheral Vascular Intervention

Antiaggregation indication after peripheral intervention (PVI) can vary up to 50% depending on center, operator, and procedure. 

Seguridad de combinar los nuevos anticoagulantes y la doble antiagregación

This highlights the huge variation in indication and the scarce evidence there is on this matter. 

Most cardiologists would like to simply transfer the information from the coronaries to the superficial femoral, but we can confirm this does not a one size fit all. Why should it work for antiaggregation? 

The guidelines recommend dual antiaggregation therapy, though based on little to no information. 

This retrospective analysis included 16,597 patients undergoing peripheral vascular intervention (PVI) between 2017 and 2018. Patients with prior anticoagulation or dual antiaggregation indication were excluded. 


Read also: Consensus on How to Conduct Follow-Up in Peripheral Vascular Disease.


Antiaggregation schemes at discharge were classified in dual antiaggregation therapy (DAPT), aspirin monotherapy, P2Y12 receptor inhibitor monotherapy, or no drug.

49% of the population was discharged with DAPT. Being a man, a smoker and having a history of CAD were clinical predictors of DAPT. 

Requiring multiple procedures, receiving a stent, and presenting any complication also resulted DAPT predictors.


Read also: Peripheral Artery Disease: Underestimated and Undertreated.


There are both clinical and technical variables that influence indication; even whim, since operators will do whatever they deem necessary given the lack of evidence. 

On June 2020 we pointed out a similar trend towards chaos showed by a study published in Eur. J Vasc. Endovasc Surg. 

The VOYAGER PAD outcomes and its subanalysis presented at ACC 2020 and ESC 2020 only add to the prior heterogeneity on this matter.


Read also: Antiaggregation vs. Anticoagulation after Peripheral PCI.


Both studies, together with the COMPASS, support the use of rivaroxaban in patients with peripheral vascular disease.  

It will take time for all this information to appear in the guidelines. On the other hand, we clearly need more studies.

Original Title: Discharge Prescription Patterns for Antiplatelet Therapy Following Lower Extremity Peripheral Vascular Intervention.

Reference: Nikhil Singh et al. Circ Cardiovasc Interv. 2020;13:e008791.  DOI: 10.1161/CIRCINTERVENTIONS.119.008791.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TCT 2024 | SIRONA: Randomized Study Comparing Sirolimus-Coated vs Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Disease

This prospective, randomized, multicenter, investigator-initiated non-inferiority study compared the use of sirolimus-coated balloon (MagicTouch) vs paclitaxel-coated balloon in endovascular treatment.  The primary objective was to...

TCT 2024 | PEERLESS: Mechanical Thrombectomy with FlowTriever vs Catheter-Directed Thrombolysis in Intermediate Risk PTE

Pulmonary embolism (PE) continues to be the third cause of cardiovascular mortality. The current clinical guidelines recommend anticoagulation in intermediate risk patients presenting right...

STEACS and the Use of Bivalirudin vs. Heparin: In Search of BRIGHT-4 Outcomes

Various studies and registries have previously shown the impact of post-percutaneous coronary intervention (PCI) complications on the survival of patients with ST-segment elevation acute...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...